囊腫纖維化治療市場機會、成長促進因素、產業趨勢分析及預測（2026-2035年）

2025 年全球囊腫纖維化治療市場價值為 181 億美元，預計到 2035 年將以 16% 的複合年成長率成長至 797 億美元。

囊腫纖維化盛行率的不斷上升以及人們對提高治療效果和改善患者預後的日益關注。早期診斷意識的提高和診斷技術的進步使得疾病的早期發現成為可能，從而推動了標靶治療的普及。持續的研發投入加速了治療方法的創新，催生了更先進、更有效的治療方案。囊腫纖維化的治療涵蓋了多種旨在控制症狀和改善患者生活品質的療法。作為一種影響多個器官系統的遺傳性疾病，對全面、專業的治療策略的需求日益成長。先進治療方法的出現以及現有療法的改進，都為市場帶來了益處，這些治療方法正在改善臨床療效。持續的創新和治療選擇的拓展正在創造新的成長機遇，並增強囊腫纖維化治療市場的整體前景。

預計到2025年，藥品市場規模將達到162億美元，繼續維持其市場主導地位。該領域涵蓋多種藥物療法，旨在控制症狀並解決潛在的疾病機制。藥物研發的加速發展推動了對能夠改善患者反應和整體治療效果的有效藥物的需求成長。針對特定疾病特徵的標靶治療的出現，也促進了該領域的強勁表現。藥物研發的持續進步正在提高治療效果，支持疾病的長期管理，並進一步鞏固藥物療法在囊腫纖維化治療市場的重要性。

到2025年，18歲以下人口將佔市場佔有率的76.9%，反映出該疾病對年輕人的重大影響。由於發病年齡較早，因此需要快速診斷和及時干預，從而推動了對兒童專科治療方案的需求。對早期疾病管理的日益重視以及先進診斷工具的普及，促進了該年齡層更廣泛地接受治療方法。看護者意識提升的提高和醫療保健服務的可近性也進一步推動了該細分市場的成長。此外，兒童治療領域持續的研究和監管支持正在鞏固該細分市場的地位，並確保其在整個預測期內保持主導地位。

預計到2025年，北美囊腫纖維化治療市佔率將達到74.5%。這主要得益於其完善的醫療基礎設施和先進的治療方法的普及。該地區擁有眾多行業巨頭和成熟的醫療體系，有利於創新治療方法的廣泛應用。優惠的報銷機制和保險覆蓋範圍也使得高成本的治療方法更容易被病人接受。持續加大對研究、早期診斷項目和治療方法創新的投入，也為市場的持續成長提供了支持。該地區致力於改善患者預後和擴大醫療服務覆蓋範圍，進一步鞏固了其在全球囊腫纖維化治療市場的領先地位。

目錄

第1章：調查方法

• 市場範圍和定義
• 研究途徑
• 對品質的承諾
  • GMI的AI政策與對資料完整性的承諾
    • 資訊來源一致性協議
• 調查過程和可靠性評分
  • 研究路徑的組成部分
  • 評分組成部分
• 數據收集
  • 主要來源部分列表
• 資料探勘資訊來源
  • 付費資訊來源
    • 區域資訊來源
• 基本估算和計算方法
  • 收入佔有率分析
  • 基準年的計算
• 預測模型
• 關於調查透明度的補充信息
  • 資訊來源歸屬框架
  • 品質保證指標
  • 對信任的承諾

第2章執行摘要

第3章業界考察

• 產業生態系分析
• 影響產業的因素
  • 成長促進因素
    • 囊腫纖維化患者數量增加
    • CFTR調變器療法的進展
    • 加大研發投入
    • 政府支持和舉措
  • 產業潛在風險與挑戰
    • 高昂的醫療費用
    • 目前治療方法的副作用
  • 市場機遇
    • 聯合治療與下一代CFTR調變器的研發
    • 數位健康與遠端患者監護的整合
• 成長潛力分析
• 監理情勢（基於初步調查）
  • 北美洲
  • 歐洲
  • 亞太地區
• 科技與創新趨勢
  • 當前技術趨勢
  • 新興技術
• 管道分析（基於初步調查）
• 流行病學情況（基於初步調查）
• 人工智慧和生成式人工智慧對市場的影響
• 波特的分析
• PESTEL 分析

第4章 競爭情勢

• 介紹
• 企業市佔率分析
• 企業矩陣分析
• 主要市場公司的競爭分析
• 競爭定位矩陣
• 主要進展
  • 併購
  • 夥伴關係與合作
  • 新產品發布
  • 業務拓展計劃

第5章 市場估計與預測：依類型分類，2022-2035年

• 製藥
  • 藥物類別
    • CFTR調變器
    • 黏液溶解劑
    • 支氣管擴張劑
    • 抗感染藥物
    • 胰酵素替代療法
    • 其他藥物分類
• 透過行政途徑
  • 口服
  • 吸入
• 透過分銷管道
  • 醫院藥房
  • 零售藥房
  • 網路藥房
• 非藥品

第6章 市場估計與預測：依年齡層別分類，2022-2035年

• 18歲以下
• 18-40歲
• 41歲或以上

第7章 市場估計與預測：依地區分類，2022-2035年

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙
  • 荷蘭
  • 愛爾蘭
  • 丹麥
• 亞太地區
  • 印度
  • 日本
  • 澳洲
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第8章：公司簡介

• Alcresta Therapeutics
• Baxter
• Chiesi Farmaceutici
• F. Hoffmann-La Roche
• Gilead
• Koninklijke Philips
• Lupin
• Monaghan Medical
• Novartis
• Savara
• Sionna Therapeutics
• Teva Pharmaceutical Industries
• Vertex Pharmaceuticals

The Global Cystic Fibrosis Therapeutics Market was valued at USD 18.1 billion in 2025 and is estimated to grow at a CAGR of 16% to reach USD 79.7 billion by 2035.

Market expansion is driven by the increasing incidence of cystic fibrosis and the growing focus on improving treatment effectiveness and patient outcomes. Rising awareness regarding early diagnosis and advancements in diagnostic technologies are supporting the timely identification of the condition, which is encouraging the adoption of targeted therapies. Continued investment in research and development is accelerating innovation in treatment approaches, leading to the introduction of more advanced and effective therapeutic solutions. Cystic fibrosis therapeutics include a wide range of treatment options designed to manage symptoms and improve the quality of life for affected individuals. As a genetic condition impacting multiple organ systems, the need for comprehensive and specialized treatment strategies is increasing. The market is benefiting from the emergence of advanced therapies and improvements in existing treatment modalities, which are enhancing clinical outcomes. Ongoing innovation and the expanding availability of treatment options are creating new growth opportunities and strengthening the overall outlook of the cystic fibrosis therapeutics market.

The medication segment accounted for USD 16.2 billion in 2025, maintaining a dominant share within the market. This segment includes multiple categories of drug therapies designed to manage symptoms and address underlying disease mechanisms. Increasing advancements in pharmaceutical development are driving demand for effective medications that improve patient response and overall treatment outcomes. The availability of targeted therapies that focus on specific disease characteristics is contributing to the segment's strong performance. Continuous progress in drug development is enhancing treatment efficacy, supporting long-term disease management, and reinforcing the importance of medication-based approaches in the cystic fibrosis therapeutics market.

The segment below 18 years held a share of 76.9% in 2025, reflecting the significant impact of the condition within younger populations. Early onset of the disease necessitates prompt diagnosis and timely intervention, which is driving demand for specialized pediatric treatment options. Increased focus on early-stage disease management and the availability of advanced diagnostic tools are supporting higher treatment adoption in this age group. Caregiver awareness and improved access to healthcare services are further contributing to segment growth. In addition, ongoing research efforts and regulatory support for pediatric treatments are strengthening the segment's position and ensuring continued dominance throughout the forecast period.

North America Cystic Fibrosis Therapeutics Market accounted for 74.5% share in 2025, driven by strong healthcare infrastructure and high accessibility to advanced treatment options. The region benefits from the presence of leading pharmaceutical companies and well-established healthcare systems that support widespread adoption of innovative therapies. Favorable reimbursement frameworks and insurance coverage are enabling broader patient access to high-cost treatments. Continued focus on research, early diagnosis programs, and treatment innovation is supporting sustained market growth. The region's commitment to improving patient outcomes and expanding access to care is reinforcing its leadership in the global cystic fibrosis therapeutics market.

Key players operating in the Global Cystic Fibrosis Therapeutics Market include Alcresta Therapeutics, Baxter, Chiesi Farmaceutici, F. Hoffmann-La Roche, Gilead, Koninklijke Philips, Lupin, Monaghan Medical, Novartis, Savara, Sionna Therapeutics, Teva Pharmaceutical Industries, and Vertex Pharmaceuticals. Companies in the Global Cystic Fibrosis Therapeutics Market are adopting a range of strategic initiatives to strengthen their market position and expand their global presence. Industry participants are heavily investing in research and development to advance innovative therapies and improve treatment effectiveness. Strategic collaborations, partnerships, and licensing agreements are being pursued to accelerate drug development and enhance technological capabilities. Organizations are also focusing on expanding their product portfolios to address diverse patient needs and improve treatment accessibility. Efforts to secure regulatory approvals and streamline commercialization processes are further supporting market expansion.

Table of Contents

Chapter 1 Research Methodology

• 1.1 Market scope and definition
• 1.2 Research approach
• 1.3 Quality commitments
  • 1.3.1 GMI AI policy and data integrity commitment
    • 1.3.1.1 Source consistency protocol
• 1.4 Research trail and confidence scoring
  • 1.4.1 Research trail components
  • 1.4.2 Scoring components
• 1.5 Data collection
  • 1.5.1 Partial list of primary sources
• 1.6 Data mining sources
  • 1.6.1 Paid sources
    • 1.6.1.1 Sources, by region
• 1.7 Base estimates and calculations
  • 1.7.1 Revenue share analysis
  • 1.7.2 Base year calculation
• 1.8 Forecast model
• 1.9 Research transparency addendum
  • 1.9.1 Source attribution framework
  • 1.9.2 Quality assurance metrics
  • 1.9.3 Our commitment to trust

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Type trends
  • 2.2.3 Age group trends
• 2.3 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing incidence rate of cystic fibrosis patient population
    • 3.2.1.2 Advancements in CFTR modulator therapy
    • 3.2.1.3 Growing investment in research and development
    • 3.2.1.4 Government support and initiatives
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High treatment costs
    • 3.2.2.2 Adverse side effects of current therapies
  • 3.2.3 Market opportunities
    • 3.2.3.1 Development of combination therapies and next-generation CFTR modulators
    • 3.2.3.2 Integration of digital health and remote patient monitoring
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape (Driven by Primary Research)
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
• 3.5 Technology and innovation landscape
  • 3.5.1 Current technological trends
  • 3.5.2 Emerging technologies
• 3.6 Pipeline analysis (Driven by Primary Research)
• 3.7 Epidemiology scenario (Driven by Primary Research)
• 3.8 Impact of AI and Generative AI on the market
• 3.9 Porter’s analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Type, 2022 - 2035 ($ Mn)

• 5.1 Key trends
  • 5.1.1 Medication
    • 5.1.1.1 By drug class
      • 5.1.1.1.1 CFTR modulators
      • 5.1.1.1.2 Mucolytic agents
      • 5.1.1.1.3 Bronchodilators
      • 5.1.1.1.4 Anti-infective agents
      • 5.1.1.1.5 Pancreatic enzyme supplements
      • 5.1.1.1.6 Other drug classes
  • 5.1.2 By route of administration
    • 5.1.2.1 Oral
    • 5.1.2.2 Inhalation
  • 5.1.3 By distribution channel
    • 5.1.3.1 Hospital pharmacies
    • 5.1.3.2 Retail pharmacies
    • 5.1.3.3 Online pharmacies
• 5.2 Non-medication

Chapter 6 Market Estimates and Forecast, By Age Group, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 Below 18 years
• 6.3 18 - 40 years
• 6.4 41 and above

Chapter 7 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 UK
  • 7.3.3 France
  • 7.3.4 Italy
  • 7.3.5 Spain
  • 7.3.6 Netherlands
  • 7.3.7 Ireland
  • 7.3.8 Denmark
• 7.4 Asia Pacific
  • 7.4.1 India
  • 7.4.2 Japan
  • 7.4.3 Australia
• 7.5 Latin America
  • 7.5.1 Brazil
  • 7.5.2 Mexico
  • 7.5.3 Argentina
• 7.6 Middle East and Africa
  • 7.6.1 South Africa
  • 7.6.2 Saudi Arabia
  • 7.6.3 UAE

Chapter 8 Company Profiles

• 8.1 Alcresta Therapeutics
• 8.2 Baxter
• 8.3 Chiesi Farmaceutici
• 8.4 F. Hoffmann-La Roche
• 8.5 Gilead
• 8.6 Koninklijke Philips
• 8.7 Lupin
• 8.8 Monaghan Medical
• 8.9 Novartis
• 8.10 Savara
• 8.11 Sionna Therapeutics
• 8.12 Teva Pharmaceutical Industries
• 8.13 Vertex Pharmaceuticals